Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial

Sircar, Dipankar; Chatterjee, Soumya; Waikhom, Rajesh; Golay, Vishal; Raychaudhury, Arpita; Chatterjee, Suparna; Pandey, Rajendra

doi:10.1053/j.ajkd.2015.05.017

Cited by 260 publications

(229 citation statements)

References 27 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…However, previous information on the efficacy and safety of febuxostat use in CKD patients above stage 3 is limited. Several studies explored the efficacy and safety of using febuxostat for treating patients undergoing advanced CKD treatment (Table 5) (Sircar et al, 2015;Saag et al, 2016;Hira et al, 2015;Juge et al, 2017;Shibagaki et al, 2014;Sakai et al, 2014). However, because of the limited number of patients included in this study and lower dosages used, further research is required for verifying the results.…”

Section: Discussionmentioning

confidence: 99%

“…Whereas the eGFR slope was negative before febuxostat administration, it became positive after febuxostat treatment (Figure 2). The prospective study by Sircar et al showed that decreasing sUA levels may slow the progress of CKD (Sircar et al, 2015). Shibagaki et al analyzed the 6-month treatment effect in patients with CKD at different stages.…”

Section: Safetymentioning

confidence: 99%

“…Previous studies have shown that hyperuricemia is associated with an increased plasma creatinine level, which is a risk factor for a low estimated glomerular filtration rate (eGFR), and can affect the progress of renal disease (Sircar et al, 2015). The risk of kidney failure is eight times higher in patients with serum uric acid (sUA) levels >8.5 mg/dl than in those with sUA levels of 5.0 to 6.4 mg/dl (Saag et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Febuxostat in patients with hyperuricemia and severe chronic kidney disease

Yang¹

2018

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

Febuxostat is a non-purine, selective inhibitor of both isoforms of xanthine oxido-reductase (XOR).Its pharmacokinetics is not dependent on renal clearance, and it may be advantageous in patients with chronic kidney disease (CKD). Although febuxostat is effective in patients with mild-to-moderate CKD, its efficacy and safety in patients with severe CKD remain unclear. This retrospective study included patients with an estimated glomerular filtration rate (eGFR) of < 30 ml/min/1.73 m 2 and hyperuricemia, who received febuxostat. The study was performed at Kaohsiung Medical University Hospital between January, 2015 and December, 2015. Changes were observed in the serum uric acid level, rate of achieving the target uric acid level (<6.0 mg/dL), changes in the eGFR, treatment dosage, and adverse events. 217 patients (65.9 ± 15.1 yrs, 145 males and 72 females) with severe CKD and hyperuricemia were included. Febuxostat significantly lowered the serum uric acid level (9.4 ± 1.9 at baseline and 5.6 ± 1.9 ml/min after treatment, P < 0.001). The serum uric acid level was <6 mg/dl in 126 patients (58.1%). There were no significant changes in eGFR (17.6 ± 7.4 at baseline and 17.8 ± 8.9 ml/min after treatment, P = 0.642) or indices of liver dysfunction. Adverse events were found in 5 patients, all adverse events improved after discontinuing febuxostat. This study demonstrated that febuxostat is efficacious and well tolerated in severe CKD patients with hyperuricemia, although renal function monitoring may be needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Safetymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Febuxostat in patients with hyperuricemia and severe chronic kidney disease

Yang¹

2018

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Данные другого исследования показали, что в случае назначения фебуксо-стата пациентам с подагрой снижение сывороточного уровня МК на 1 мг/дл предотвращает снижение СКФ на 1,15 мг/дл, а ожидаемое, проанализированное на основа-нии четырехлетнего наблюдения, связанное со старением снижение СКФ при отсутствии гиперурикемии сопостави-мо с таковым у пациентов, получающих фебуксостат, тогда как у пациентов с нелеченой гиперурикемией скорость снижения СКФ была много большей [27]. У пациентов с асимптоматической гиперурикемией и средней СКФ 31,5 мл/мин/1,73 м 2 6-месячный курс терапии фебуксостатом в дозе 40 мг способствовал увеличению СКФ в среднем более чем на 10% относительно исходного значения, в то время как при приеме плацебо снижение СКФ за тот же период времени составило 13,5% [28].…”

Section: фебуксостатunclassified

Pneumocystic Pneumonia in Rheumatic Diseases: Current Issues in Prophylaxis

Елисеев¹

2017

Med. sov.

View full text Add to dashboard Cite

Ключевым медикаментозным методом лечения подагры является уратснижающая терапия, назначение которой в клини-ческой практике сопряжено с высокой вероятностью ошибок из-за незнания показаний к ней, принципов выбора и правил назначения конкретных препаратов. В статье обсуждены показания к уратснижающей терапии у пациентов с подагрой, цели такой терапии, приведены данные о доступных в РФ уратснижающих препаратах (аллопуринол, фебуксостат).Ключевые слова: подагра, мочевая кислота, уратснижающая терапия, аллопуринол, фебуксостат. M.S. ELISEEV, PhD in medicine, Nasonova Research Institute of Reumatology В.А. Moscow URATELOWERING THERAPY OF GOAT: BASIC PRINCIPLES AND REAL OPPORTUNITIESUrate-lowering therapy is the key pharmaceutical method of treating gout, which appointment in clinical practice is associated with a high probability of errors due to ignorance of the indications for it, the principles of choice and the rules for prescribing specific drugs. The article discusses indications for urate-lowering therapy in patients with gout, the objectives of such therapy, and provides data on the urate-lowering drugs available in the Russian Federation (allopurinol, febuxostat).

show abstract

“…In addition, a recent meta-analysis showed a significant favorable effect of allopurinol on the rate of GFR decline [103] . Another recent trial demonstrated the significant impact of febuxostat on CKD progression in stage G3 and G4 patients [104] . Correction of chronic metabolic acidosis was originally recommended in CKD patient to inhibit excessive protein catabolism and calcium mobilization out of the bone.…”

Section: Pathogenesismentioning

confidence: 99%

Stop chronic kidney disease progression: Time is approaching

Din¹,

Salem²,

Abdulazim³

2016

WJN

View full text Add to dashboard Cite

Progression of chronic kidney disease (CKD) is inevitable. However, the last decade has witnessed tremendous achievements in this field. Today we are optimistic; the dream of withholding this progression is about to be realistic. The recent discoveries in the field of CKD management involved most of the individual diseases leading the patients to end-stage renal disease. Most of these advances involved patients suffering diabetic kidney disease, chronic glomerulonephritis, polycystic kidney disease, renal amyloidosis and chronic tubulointerstitial disease. The chronic systemic inflammatory status and increased oxidative stress were also investigated. This inflammatory status influences the antisenescence Klotho gene expression. The role of Klotho in CKD progression together with its therapeutic value are explored. The role of gut as a major source of inflammation, the pathogenesis of intestinal mucosal barrier damage, the role of intestinal alkaline phosphatase and the dietary and therapeutic implications add a novel therapeutic tool to delay CKD progression.

show abstract

Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial

Cited by 260 publications

References 27 publications

Febuxostat in patients with hyperuricemia and severe chronic kidney disease

Febuxostat in patients with hyperuricemia and severe chronic kidney disease

Pneumocystic Pneumonia in Rheumatic Diseases: Current Issues in Prophylaxis

Stop chronic kidney disease progression: Time is approaching

Contact Info

Product

Resources

About